Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial

The Lancet Infectious Diseases
Michael T WhiteAzra C Ghani

Abstract

The RTS,S/AS01 malaria vaccine targets the circumsporozoite protein, inducing antibodies associated with the prevention of Plasmodium falciparum infection. We assessed the association between anti-circumsporozoite antibody titres and the magnitude and duration of vaccine efficacy using data from a phase 3 trial done between 2009 and 2014. Using data from 8922 African children aged 5-17 months and 6537 African infants aged 6-12 weeks at first vaccination, we analysed the determinants of immunogenicity after RTS,S/AS01 vaccination with or without a booster dose. We assessed the association between the incidence of clinical malaria and anti-circumsporozoite antibody titres using a model of anti-circumsporozoite antibody dynamics and the natural acquisition of protective immunity over time. RTS,S/AS01-induced anti-circumsporozoite antibody titres were greater in children aged 5-17 months than in those aged 6-12 weeks. Pre-vaccination anti-circumsporozoite titres were associated with lower immunogenicity in children aged 6-12 weeks and higher immunogenicity in those aged 5-17 months. The immunogenicity of the booster dose was strongly associated with immunogenicity after primary vaccination. Anti-circumsporozoite titres wane accordi...Continue Reading

References

May 22, 1998·American Journal of Epidemiology·L K DurhamM Rao
Feb 24, 2006·Nature Reviews. Immunology·Adrian V S Hill
Oct 9, 2007·The Journal of Infectious Diseases·Li QinSteven G Self
Nov 9, 2007·The New England Journal of Medicine·Ian J AmannaMark K Slifka
Jul 20, 2010·Immunological Reviews·Ian J Amanna, Mark K Slifka
Oct 15, 2010·Proceedings. Biological Sciences·Michael T WhiteChandy C John
Dec 24, 2010·Nature Reviews. Immunology·Robert W SauerweinVasee S Moorthy
Aug 6, 2011·Malaria Journal·Christine SwysenUNKNOWN Clinical Trials Partnership Committee
Feb 7, 2013·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Stanley A Plotkin
Mar 5, 2013·The Lancet Infectious Diseases·Philip BejonAzra C Ghani
Mar 22, 2013·The New England Journal of Medicine·Ally OlotuPhilip Bejon
Apr 20, 2013·Proceedings of the National Academy of Sciences of the United States of America·Else M BijkerRobert W Sauerwein
Apr 11, 2014·The Journal of Infectious Diseases·Michael T WhiteAzra C Ghani

❮ Previous
Next ❯

Citations

Nov 13, 2015·Expert Review of Vaccines·Eizo TakashimaTakafumi Tsuboi
Jan 14, 2016·Expert Review of Vaccines·Kazutoyo Miura
Sep 8, 2015·The Lancet Infectious Diseases·Takafumi Tsuboi, Eizo Takashima
Jul 11, 2016·The Lancet Infectious Diseases·James G Beeson, Freya J I Fowkes
Sep 12, 2016·Trends in Molecular Medicine·Pamela M Odorizzi, Margaret E Feeney
Jun 22, 2016·Expert Review of Vaccines·Michael R Hollingdale, Martha Sedegah
Dec 21, 2016·Scientific Reports·Sophie DetienneArnaud M Didierlaurent
Apr 14, 2016·PLoS Medicine·Roly Gosling, Lorenz von Seidlein
Feb 6, 2017·Molecular Therapy : the Journal of the American Society of Gene Therapy·Carly M BlissKatie J Ewer
May 16, 2017·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Gemma MoncunillCarlota Dobaño
Jun 25, 2017·Immunology·James TujuFaith H A Osier
Jun 13, 2017·Expert Review of Vaccines·Edward H NtegeTakafumi Tsuboi
Mar 10, 2018·NPJ Vaccines·Camila Henriques CoelhoPatrick E Duffy
Mar 1, 2017·Cold Spring Harbor Perspectives in Medicine·Teun Bousema, Chris Drakeley
May 12, 2017·Clinical and Vaccine Immunology : CVI·Xin-Xing GuChristopher E Taylor
Dec 18, 2015·Clinical and Vaccine Immunology : CVI·Matthew B Laurens
Nov 30, 2018·Immunology·Rachel Wong, Deepta Bhattacharya
Jan 3, 2019·Expert Review of Vaccines·K L WilsonM Plebanski
Nov 15, 2016·Expert Review of Vaccines·Pascale Vandoolaeghe, Lode Schuerman
Sep 24, 2019·Human Vaccines & Immunotherapeutics·Matthew B Laurens
Jun 12, 2020·Immunological Investigations·Cecilia NapodanoUmberto Basile
Mar 18, 2020·FEBS Letters·Patience Kerubo KiyukaAyman Khattab
Mar 1, 2017·Frontiers in Immunology·Carolina LópezManuel A Patarroyo

❮ Previous
Next ❯

Methods Mentioned

BETA
enzyme-linked immunosorbent assays

Software Mentioned

Nanoro

Related Concepts

Related Feeds

Antimalarial Agents (ASM)

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

Antimalarial Agents

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.